FOLH1 and prostate carcinoma: [68Ga]Ga-PSMA-11 PET/CT identified positive regions within the prostate with a sensitivity of 67% and a specificity of 92% in patients with biopsy-proven prostate cancer, thereby suggesting a potential future role of PSMA-11 in PET-guided biopsy.